<DOC>
	<DOCNO>NCT03042260</DOCNO>
	<brief_summary>The purpose study determine whether trimethoprim/sulfamethoxazole effective prevent serious infectious complication ( require hospitalization lead death ) patient lupus erythematosus receive intermediate high dose steroid .</brief_summary>
	<brief_title>Prophylactic Trimethoprim/Sulfamethoxazole Prevent Severe Infections Patients With Lupus Erythematous</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<mesh_term>Sulfamethoxazole</mesh_term>
	<mesh_term>Trimethoprim</mesh_term>
	<mesh_term>Trimethoprim , Sulfamethoxazole Drug Combination</mesh_term>
	<criteria>Systemic Lupus Erythematosus accord American College Rheumatology Criteria On daily dose corticosteroid â‰¥ 0.5 mg/kg/d , expect remain dose least 1 month . Have sign inform consent Absolute contraindication receive TMPSMX ( know allergy TMPSMX sulfa drug ; TMPSMX induce thrombocytopenia ) Received TMPSMX treatment previous month The presence concomitant rheumatologic autoimmune disease exception antiphospholipid syndrome Creatinine clearance &lt; 30ml/min/m2 Chronic viral infection ( Hepatitis C virus , Hepatitis B virus , Human immunodeficiency virus ) Malignant neoplasm , except skin neoplasm Primary immune deficiency Solid organ hematopoietic stem cell transplant recipient Pregnancy Breastfeeding Current active infection 2 week prior . Absolute Neutrophil Count &lt; 750/mm3 , platelet &lt; 30x10^9/L , hemoglobin &lt; 8 g/dL Patients receive Methotrexate Patients participate another research study judgement principal investigator could jeopardize safety efficacy study drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>trimethoprim , sulfamethoxazole drug combination</keyword>
	<keyword>Infection</keyword>
	<keyword>Prophylaxis</keyword>
</DOC>